Next-generation sequencing (NGS) is quickly revolutionizing how research into the genetic determinants of constitutional disease is performed. The technique is highly efficient with millions of sequencing reads being produced in a short time span and at relatively low cost. Specifically, targeted NGS is able to focus investigations to genomic regions of particular interest based on the disease of study. Not only does this further reduce costs and increase the speed of the process, but it lessens the computational burden that often accompanies NGS. Although targeted NGS is restricted to certain regions of the genome, preventing identification of potential novel loci of interest, it can be an excellent technique when faced with a phenotypically and genetically heterogeneous disease, for which there are previously known genetic associations. Because of the complex nature of the sequencing technique, it is important to closely adhere to protocols and methodologies in order to achieve sequencing reads of high coverage and quality.
Introduction
As defining the genetic determinants of various conditions takes on a higher priority in research and in the clinic, next-generation sequencing (NGS) is proving to be a high-throughput and cost-effective tool to achieve these goals 1, 2, 3 . For almost 40 years, Sanger sequencing had been the gold standard for identifying genetic variants 4 ; however, for diseases with genetic heterogeneity or unknown genetic etiology, many possible candidate genes must be evaluated, often concurrently. In this context, Sanger sequencing becomes expensive and time-consuming. However, NGS involves massive parallel sequencing of millions of DNA fragments, allowing for a cost and time efficient technique to simultaneously detect a wide range of genetic variation across various regions of the genome.
There are three types of NGS for sequencing DNA: 1) whole-genome sequencing (WGS), 2) whole-exome sequencing (WES), and 3) targeted sequencing 5 . WGS evaluates the entire genomic content of an individual, while WES involves sequencing only the protein-coding regions of the genome 6 . Targeted sequencing, in contrast, focuses on specific regions of the genome based on relatively few specific genes linked by common pathological mechanisms or known clinical phenotype. Either the exons or introns, or any intergenic regions of a gene or specific group of genes can be specified using this approach. Therefore, targeted sequencing can be an excellent approach when there is already a foundation of candidate genes known to be associated with the disease of interest. Targeting specific regions of the genome allows for elimination of superfluous and irrelevant genetic variation that can cloud or distract from clinical interpretation. While WGS and WES both produce a large amount of high-quality data, the amount of data can be overwhelming. Not only does this large amount of data require computationally intensive bioinformatics analysis, but data storage can frequently present problems 7 . This challenge of data storage also adds additional costs to both WGS and WES, which is often not initially considered when calculating the expense of sequencing. Further, although it is decreasing, the cost of WGS and WES remain relatively high. Targeted sequencing can be a more cost-efficient option, particularly when sequencing of a large number of individuals is required.
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a multi-platform, provincial-wide, observational cohort study characterizing five neurodegenerative diseases, including: 1) Alzheimer's disease and mild cognitive impairment, 2) amyotrophic lateral sclerosis, 3) frontotemporal dementia, 4) Parkinson's disease, and 5) vascular cognitive impairment 8 . The ONDRI genomics subgroup is aiming to elucidate as part of the baseline characterization of this cohort the often discounted, yet extremely important genetic landscape of these phenotypically and genetically heterogeneous diseases. Neurodegenerative diseases are thus appropriate candidates for NGS methodologies and for targeted sequencing in particular.
We have custom-designed a targeted NGS panel, ONDRISeq, to sequence 528 participants involved in ONDRI for the protein-coding regions of 80 genes that have been previously associated with the five diseases of interest. With this methodology, we are able to harness the highquality NGS data in a focused and efficient manner. The design and validation of the ONDRISeq panel with multiple concordance studies has been previously described, for which the ONDRISeq panel was able to identify novel, rare variants of possible clinical significance in 72.2% of 216 cases used for panel validation 9 . Although NGS technology has advanced rapidly and remarkably in recent years, many researchers face a challenge when processing the raw data into a list of usable, annotated variants 10 . Further, interpretation of the variants can be complex, especially when faced with many that are rare or novel 11 .
Here, we describe in a step-by-step manner, the methodology of targeted NGS and the associated bioinformatics workflow required for resequencing, variant calling, and variant annotation using the ONDRISeq study as an example. After the generation of NGS data, raw sequencing files must be aligned to the human reference genome in order to accurately call variants. Variants must then be annotated in order to perform subsequent variant curation. We will also explain our implementation of the American College of Medical Genetics' Standards and Guidelines to accurately classify variant pathogenicity.
Protocol
For the purposes of ONDRI, ethics protocols and informed consent were obtained based on the Research Ethic Boards at Baycrest Centre for Geriatric Care (Toronto, Ontario, Canada); Centre for Addiction and Mental Health (Toronto, Ontario, Canada); Elizabeth Bruyère Hospital (Ottawa, Ontario, Canada); Hamilton General Hospital (Hamilton, Ontario, Canada); London Health Sciences Centre (London, Ontario, Canada); McMaster (Hamilton, Ontario, Canada); The Ottawa Hospital (Ottawa, Ontario, Canada); Parkwood Hospital (London, Ontario, Canada); St Michael's Hospital (Toronto, Ontario, Canada); Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada); and University Health NetworkToronto Western Hospital (Toronto, Ontario, Canada).
manufacturer's instructions. NOTE: The concentration of the sample should be >10 ng/µL because of the lower sensitivity of the spectrophotometer used previously. 5. Based on the concentration measured, dilute 20 µL of the DNA to 10 ng/µL using 10 µM Tris buffer pH 8.5 and allow the sample to sit overnight at 4 °C. 6. Measure DNA concentration with the fluorometer 14 , according to manufacturer's instructions. 7. Based on the concentration measured, dilute 10 µL of the DNA to 5 ng/µL using 10 µM Tris-HCl pH 8.5 and allow the sample to sit overnight at 4 °C. 14 , according to manufacturer's instructions. Use this concentration to determine the volume of each DNA library to pool to obtain the equimolar ratios recommended by the target enrichment kit being used.
Next-generation Sequencing
1. Sequence the library according to the NGS desktop instrument's reagent kit manufacturer's instructions 17, 18 (Table of Materials).
1. Prepare a sample sheet according to manufacturer's instructions 18 using the appropriate NGS technology software (Table of Materials), which will be imported into the NGS desktop instrument's workflow. NOTE: For the purposes of ONDRISeq, the application option chosen is 'other', with only the FASTQ files requested (Figure 1) . Subsequent steps will process these FASTQ files, to allow for full customization of alignment and quality parameters. However, if targeted sequencing is chosen, some NGS instruments are able to process the sequencing data into VCF files themselves. The manufacturer's instructions 18 may be consulted for a full selection of options.
2. If using a cloud-based computing environment 19 ( NOTE: Average library size will be specific to target enrichment kit being used, and can be obtained from the electrophoresis trace observed in step 3.1.4. 6. Dilute the sequencing library to a final concentration of 6-20 pM, as appropriate, and volume of 600 μL, according to manufacturer's instructions 21 . NOTE: The exact concentration needed is dependent on the sequencing kit used. Consult the enrichment kit manufacturer to determine the proper loading concentration. 7. Dilute, denature, and include a positive control sequencing library 21 , according to the manufacturer's instructions. 8. Keep a log of every sequencing run, which includes the DNA library concentration loaded (pM), the percentage of positive control added, reagent cartridge barcode, application chosen in step 3.1.1, number of index reads, enrichment kit used, read length(s), and the sample sheet name. NOTE: The run time of the NGS desktop instrument will depend on the instrument, enrichment kit, and read lengths chosen (4-56 h for the sequencer used in this experiment 1. From the Run Charts page, find the figure labeled "Data by Cycle". Under chart, select "Intensity" and under channel select "All Channels". Ensure that this signal intensity plot produced is similar to that produced by sequencing runs performed in the past with the same enrichment kit and NGS desktop instrument. NOTE: This reflects the percentage of intensity shown by each base across all 150 cycles. The figure can vary widely depending on the enrichment kit used, which is why it must be compared to past sequencing runs of the same panel. 2. Select the "Indexing QC" tab within the run navigation panel to find the indexing quality control (QC) histogram, which is on the righthand side of the page. Ensure that a relatively uniform distribution of % Reads Identified (PF) is observed across all samples. NOTE: If any samples have a much lower % Reads Identified (PF) than the rest of the samples, note that the quality of the sequencing data may be affected.
4.
From the Run Summary page of the cloud-based computing environment, navigate to the quality metrics by clicking "Metrics" within the run navigation panel. NOTE: Metrics cut-offs will depend on the sequencing platform and enrichment kit being used. There are many metrics that can be utilized based on manufacturer's instructions 23 , with the following steps highlighting three that are highly recommended for quality control.
Under "DENSITY (K/MM
2 )" ensure the cluster density is within the range recommended by the enrichment kit being used (in this case 1,200-1,400 K/mm 2 ). 2. Under the total "%≥Q30" ensure that the value is ≥85%, reflecting the quality of the sequencing reads.
NOTE: If lower than this threshold of 85%, note that the quality of the sequencing may be compromised. 3. Under "ALIGNED (%)" ensure that the value is similar to the % of positive control that was included in the sequencing run.
NOTE: This acts as a measure of positive control, such that only this percentage of total reads were found to align to the positive control genome. If 1% positive control was used it would be expected that the Aligned (%) would be ~1-5%. (Table of Materials) sample sheet creator application options. For the purposes of ONDRISeq, the FASTQ only application is used. However, if the user would like other files produced, such as VCF files, it is recommended that an application within the targeted resequencing category is used. Please click here to view a larger version of this figure.
Resequencing and Variant Calling
1. For data pre-processing, select appropriate software to align the raw FASTQ files to the human reference genome and to call variants (Table  of Materials) . 2. Import FASTQ sequencing reads into the data pre-processing software.
NOTE: For the purposes of ONDRISeq, the 48 FASTQ files produced from a single sequencing run of 24 samples are imported and processed through the software. The number of samples processed at once can vary depending on the needs of the researcher and size of the NGS panel.
1. Within the "Navigation Area", right click and select "New Folder". Name the folder such that there is clarity as to the sequencing run that was performed. 2. From the toolbar at the top, select "Import". From the dropdown list of sequencing platforms shown chose the platform with which the sequencing was performed. . 3. In the dialog box, navigate to and select the FASTQ files from the sequencing run that is being processed. Ensure that the files being imported are stored in and imported from the local drive, if using a computer with multiple servers. 4. From the "General options" of the dialog box, click the box beside "Paired reads" if sequencing used paired end chemistries.
NOTE: In this case, there should also be two FASTQ samples imported for each sample -one forward and one reverse. 5. From the Paired read information of the dialog box, select "Paired-end (forward-reverse)" if the forward read FASTQ file appears before the reverse read in the file list. If the files appear in the opposite order, select "Mate-pair (reverse-forward)". Set the paired read minimum distance to 1 and maximum distance to 1000, to allow for the detection of small scale structural rearrangements within the sample sequences. 6. From the "Illumina options" of the dialog box, select "Remove failed reads", to remove the reads that failed sequencing. If the NGS desktop instrument de-multiplexed the data before exporting the FASTQ files do not select the "MiSeq de-multiplexing" box. 7. From the "Quality score" dropdown list, select the NGS Pipeline that was utilized for sequencing. Select "Next" at the bottom of the dialog box. NOTE: The pipeline used will affect the format of the FASTQ file quality scores. For more information about which pipeline to select, consult the manufacturer's instructions 24 . 8. From the new dialog box, select "Save" and "Create subfolders per bath unit to put each sample's FASTQ files into their own individual folder. Select "Next" at the bottom of the dialog box. 9. From the new dialog box, choose the folder that was created in step 4.2.1. This is where the FASTQ files will be imported. Select "Finish" at the bottom of the dialog box and wait until the FASTQ files are imported. Click the "Processes" tab to see the status of the file import.
3. Design a workflow within the software to perform resequencing and variant calling, according to manufacturer's instructions. NOTE: This workflow can vary based on the needs of the researcher, but the following steps encompass what is included for the purposes of ONDRISeq (Figure 2) . The steps in this workflow can be applied to other NGS resequencing and variant calling software as appropriate. All bioinformatics processing for the purposes of ONDRI is performed in reference to human reference genome GRCH37/hg19, for consistency of data processing and analysis. 1. Map the sequencing reads to the reference genome. 1. When configuring, choose the reference genome as appropriate, ensuring that it is the same reference genome that is used for all bioinformatics steps. 2. From the masking mode drop-down list select "No masking" so that no regions of the reference sequence are masked. 3. Use the default mapping options assigned by the software. Review the manufacturer's instructions 24 to verify that this is acceptable based on the purposes of the research.
2. Include in the workflow local realignment to the human reference genome to resolve any read mapping errors, particularly surrounding insertion-deletion variants. 1. Use the default local realignment options assigned by the software. Review the manufacturer's instructions 24 to verify that this is acceptable based on the purposes of the research.
3. Remove duplicated mapped reads produced by PCR within the NGS protocol to reduce the effect of the PCR amplification bias, which may produce false positives 25 . 1. Set the "Maximum representation of minority sequence (%)", based on the needs of the research.
NOTE: A lenient setting, as used for the purposes of ONDRISeq, is 5%; however, the software's default setting is more stringent 20%. When two reads are very similar, this setting determines if the sequence with fewer read counts should be considered a sequencing error from the PCR amplification bias. Therefore, by setting 5%, the minority read count must be ≤ 5% of the majority read count to be corrected to be identical to the majority read.
4. Export statistics for the target regions in the form of a coverage summary text file from the read tracks generated in step 4.3.3. Ignore non-specific matches and broken pairs in the settings. Choose a destination on the local drive for these files. 5. Export a binary sequence alignment map (BAM) file for each sample from the read tracks generated in step 4.3.3. This contains sequence alignment data, if needed in future analyses. Choose a destination on the local drive for these files. 6. Choose a method of variant detection to call variants within the sequence.
NOTE: When assumptions can be made about the ploidy of the samples, it is recommended that a fixed ploidy variant detection algorithm be used, as is used for the purposes of ONDRISeq. If this assumption cannot be made, refer to the manufacturer's instructions 24 to determine the best algorithm for the purposes of the research.
, to make it available in the software's "Toolbox". Ensure the workflow is named such that it is clear in the future what NGS panel it is appropriate for.
1. In the dialog box with the "Exporting reference data" options during installation, set all options to "Bundle". 2. In the dialog box with the "Install location" options during installation, click "Install the workflow on your local computer".
4.
Run imported FASTQ sequencing read files through the customized bioinformatics workflow designed in step 4.3, according to manufacturer's instructions 24 . 1. Identify the workflow designed in step 4.3 in the software's "Toolbox" and double-click it. 2. Within the dialog box that appears, locate the folders of FASTQ files that were imported in step 4.2 within the "Navigation Area".
Highlight all folders by selecting them within the "Navigation Area" and then click the box beside "Batch". Use the right-facing arrow to move the files to "Selected elements". Click "Next" at the bottom of the dialog box. 3. Within the dialog box, review the "Batch overview" to ensure the correct FASTQ files were selected and then click "Next". 4. Review the following steps of the workflow within the dialog box to ensure the correct files and export locations were selected when designing the workflow in step 4.3: "Map Reads to Reference"; Remove Duplicate Mapped Reads"; "Create Statistics for Target Regions"; "Export BAM"; "Export Tab delimited text"; "Filter Based on Overlap"; and "Export VCF" 5. Within the final step in the dialog box -"Result handling"-select the option "Save in input folder". Click "Finish" at the bottom of the dialog box. NOTE: This means that the files produced for each sample will be placed into the same folder that stores the FASTQ file within the data pre-processing software. (Table of Materials) customized for the purposes of ONDRISeq. The steps in the workflow can be applied to other NGS resequencing and variant calling software based on the needs of the researcher. Please click here to view a larger version of this figure. Although not used for this study, InterVar 40 is a similarly designed tool that can be utilized in an analogous manner.
Variant Annotation
6. Sanger sequence any variants with a sequencing coverage of <30x and/or variants that have been identified in > 10% of the study cohort to validate that they are not sequencing artifacts 41 .
Representative Results
The methodologies described herein were applied to 528 participant DNA samples from individuals that have been enrolled in ONDRI. Samples were run on the ONDRISeq panel in 22 runs of 24 samples per run. Overall, sequencing data were determined to be of high quality with a mean sample coverage of 78 ± 13x and all individual runs expressed a mean sample coverage >30x. Further, on average, 94% of all target regions were covered at least 20x ( Table 1) .
A mean 95.6% of reads were mapped to the reference sequence and all ONDRISeq runs had >90% of reads mapped ( Table 1) . Of the mapped reads, 92.0% had a Phred score ≥Q30, with only one run having <80% of mapped reads meeting this quality metric. However, this run still displayed a mean coverage of 79x and 93% of target regions were covered at least 20x. Case Study: Identification of rare variants in a PD patient.
Parameter
To demonstrate the utility of our targeted NGS workflow, we present the example of a 68 year-old, male, Parkinson's disease patient. The DNA sample was run on the NGS desktop instrument ( . The patient's particular sample displayed a mean coverage of 76x, with 93.9% of the target regions covered at least 20x.
After performing variant calling and annotation with the custom bioinformatics workflow, the patient was found to harbor 1351 variants within the exons and surrounding 250 bp of the 80 genes included on the ONDRISeq panel. However, the ANNOVAR pipeline was able to reduce the number of variants by considering variant sequence ontology and MAF, as described above. This produced a list of seven variants that underwent manual curation (Figure 3) . From these seven variants, two were identified as having possible clinical significance. This process is specific to the needs of ONDRI and was done by identifying those that are relatively rare in the general population and are nonsynonymous in ontology thereby causing a change in the protein. Whether the variant had been previously associated with disease, the in silico predictions of deleteriousness to the protein and the ACMG pathogenicity classification of the variants were also utilized in this process.
. Further, mutations within this gene are known to be among the leading causes of familial Parkinson's disease 43 . This variant introduces a premature stop codon within LRRK2, thereby losing amino-acid residues 1,314-2,527. This prevents the translation of the protein's Ras of complex proteins (Roc), C-terminal of Roc (COR), and protein kinase domains, which are involved in functioning as an atypical Rho GTPase, GTP binding protein, and protein kinase, respectively, and was predicted to be damaging by the in silico analysis generated by CADD (CADD Phred = 36). This variant is also rare with a MAF of 0.004% and 0.01% in ExAC and ESP, respectively, and is absent from the 1000G database. Additionally, this is the only patient out of all 528 sequenced who carries this variant, which is novel since it has not been previously described in disease mutation databases (Table of Materials). The confidence of the variant call was confirmed by its deep coverage of 109x. Finally, the variant was assessed with the AMCG Standards and Guidelines for pathogenicity and was classified as being pathogenic.
The patient also carried a second heterozygous variant, NR4A2:c.C755A, resulting in the missense change p.P252Q. The protein encoded by NR4A2, Nuclear Receptor Subfamily 4 Group A Member 2, is a transcription factor involved in the generation of dopaminergic neurons 44 and mutations within this gene have been previously associated with Parkinson's disease 45 . The substitution of the non-polar proline to the polar glutamine was predicted to be damaging by the in silico prediction analysis generated by CADD (CADD Phred = 21.1), but not by the analysis generated by SIFT or PolyPhen-2. The variant is rare, with a MAF of 0.004% in ExAC and absence from both ESP and 1000G. The variant was also identified in an ONDRI participant diagnosed with vascular cognitive impairment, but has not been previously described in disease mutation databases. This variant had coverage of only 18x, however, Sanger sequencing will be performed in order to ensure its validity within the sequence. Finally, the variant was determined to be of uncertain significance when assessed with the ACMG Standards and Guidelines for pathogenicity.
The ONDRISeq panel and bioinformatics pipeline is also able to determine the APOE genotype of each sample. This patient was determined to have the APOE genotype E3/E3. 
Discussion
In the path from DNA sample extraction to identifying variants that may be of interest when considering a patient's diagnosis, disease progression, and possible treatment options, it is important to recognize the multifarious nature of the methodology required for both sequencing and proper data processing. The protocol described herein is an example of the utilization of targeted NGS and subsequent bioinformatic analysis essential to identify rare variants of potential clinical significance. Specifically, we present the approach taken by the ONDRI genomics subgroup when using the ONDRISeq custom-designed NGS panel.
It is recognized that these methods were developed based on a specific NGS platform and that there are other sequencing platforms and target enrichment kits that may be used. However, the NGS platform and desktop instrument (Table of Materials) was chosen based on its early US Food and Drug Administration (FDA) approval 46 . This authorization reflects the high-quality sequencing that can be performed with the NGS protocols of choice and the reliability that can be placed on the sequencing reads.
Although obtaining accurate sequencing reads with the depth of coverage is very important, the bioinformatics processing required for final rare variant analysis is vital and can be computationally intensive. Due to the many sources of errors that may occur within the sequencing process, a robust bioinformatics pipeline must correct for the various inaccuracies that can be introduced. They may arise from misalignments in the mapping process, amplification bias introduced by PCR amplification in the library preparation, and the technology producing sequencing artifacts 47 . No matter the software used to perform read mapping and variant calling, there are common ways to reduce these errors including local realignment, removal of duplicate mapped reads, and setting proper parameters for quality control when calling variants. Additionally, the parameters chosen during variant calling may vary based on what is most appropriate for the study at hand 11 . The minimum coverage and quality score of a variant and the surrounding nucleotides that were applied herein were chosen as to create a balance between appropriate specificity and sensitivity. These parameters have been validated for the ONDRISeq panel based on variant calling concordance with three separate genetic techniques, as previously described, including: 1) chip-based genotyping; 2) allelic discrimination assay; and 3) Sanger sequencing 9 .
Following accurate variant calling, in order to determine those of potential clinical significance, annotation and curation are essential. Due to its open access platform, ANNOVAR is an excellent tool for both annotation and preliminary variant screening or elimination. Beyond being easily accessible, ANNOVAR can be applied to any VCF file, no matter what sequencing platform is used, and is customizable based on the needs of the research 26 .
After annotation, variants must be interpreted to determine if they should be considered to be of clinical significance. Not only does this process become complex, but it is often prone to subjectivity and human error. For this reason, the ACMG has set guidelines to assess the evidence for pathogenicity of any variant. We apply a non-synonymous, rare variant-based manual curation approach, which is constructed based on these guidelines and safeguarded by individually assessing each variant that is able to pass through the pipeline with a custom-designed Python script that classifies the variants based on the guidelines. In this way, each variant is assigned a ranking of pathogenic, likely pathogenic, uncertain significance, likely benign, or benign, and we are able to add standardization and transparency to the variant curation process. It is important to Although the methods presented here are specific to ONDRI, the steps described can be translated when considering a large number of constitutional diseases of interest. As the number of gene associations increase for many phenotypes, targeted NGS allows for a hypothesis driven approach that can capitalize on the previous research that has been done in the field. Yet, there are limitations to targeted NGS and the methodology presented. By only focusing on specific regions of the genome, the areas of discovery are limited to novel alleles of interest. Therefore, novel genes or other genomic loci beyond those covered by the sequencing targets, which could be revealed with WGS or WES approaches, will not be identified. There are also regions within the genome that can be difficult to accurately sequence with NGS approaches, including those with a high degree of repeated sequences 48 or those that are rich in GC content 49 . Fortunately, when utilizing targeted NGS, there is a priori a high degree of familiarity with the genomic regions being sequenced, and whether these might pose technical challenges. Finally, detection of copy number variants from NGS data at present is not standardized 50 . However, bioinformatics solutions to these concerns may be on the horizon; new computational tools may help to analyze these additional forms of variation in ONDRI patients.
Despite its limitations, targeted NGS is able to obtain high-quality data, within a hypothesis-driven approach, while remaining less expensive than its WGS and WES counterparts. Not only is this methodology appropriate for efficient and directed research, the clinical implementation of targeted NGS is growing exponentially. This technology is being used to answer many different questions regarding the molecular pathways of various diseases. It is also being developed into an accurate diagnostic tool at relatively low cost when opposed to WES and WGS. Even when compared to the gold-standard Sanger sequencing, targeted NGS can outcompete in its time-and cost-efficiency. For these reasons, it is important for a scientist or clinician who receives and uses NGS data, for instance, delivered as text in a laboratory or clinical report, to understand the complex "black box" that underlies the results. The methods presented herein should help users understand the process underlying the generation and interpretation of NGS data.
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